Immune-Guided Therapy of COVID-19

Vaccination has been a game changer in our efforts to address the coronavirus disease 2019 (COVID-19) pandemic. However, the disease might still represent a clinical crisis for several more years, in part because of the inevitable emergence of variants capable of evading the preexisting immunity. Dr...

Full description

Saved in:
Bibliographic Details
Published in:Cancer immunology research 2022-04, Vol.10 (4), p.384-402
Main Authors: Ferraccioli, Gianfranco, Gremese, Elisa, Goletti, Delia, Petrone, Linda, Cantini, Fabrizio, Ugel, Stefano, Canè, Stefania, Bronte, Vincenzo
Format: Article
Language:English
Subjects:
COVID-19
Hospitalization
Humans
Pandemics
SARS-CoV-2
Vaccination
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Vaccination has been a game changer in our efforts to address the coronavirus disease 2019 (COVID-19) pandemic. However, the disease might still represent a clinical crisis for several more years, in part because of the inevitable emergence of variants capable of evading the preexisting immunity. Drugs affecting viral spread will help curtail transmission, but therapeutics are needed to treat the more severe cases requiring hospitalization. A deep analysis of the evolving immune landscape of COVID-19 suggests that understanding the molecular bases of the distinct clinical stages is paramount if we are to limit the burden of inflammation, which can lead to death in frail individuals, according to age, sex, and comorbidities. Different phases can be defined using immune biomarkers and need specific therapeutic approaches, tailored to the underlying immune contexture.
ISSN:2326-6066
2326-6074
DOI:10.1158/2326-6066.CIR-21-0675